About Semma Therapeutics
Semma Therapeutics is a company based in Cambridge (United States) founded in 2015 was acquired by Vertex Pharmaceuticals in September 2019. Semma Therapeutics has raised $158 million across 3 funding rounds from investors including Medtronic, Novartis and Vertex Pharmaceuticals. The company has 58 employees as of December 31, 2022. Semma Therapeutics has completed 1 acquisition, including CytoSolv. Semma Therapeutics operates in a competitive market with competitors including Kriya Therapeutics, Sana Biotechnology, Cellino, Adocia and Pendulum, among others.
- Headquarter Cambridge, United States
- Employees 58 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Semma Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$158 M (USD)
in 3 rounds
-
Latest Funding Round
$114 M (USD), Series B
Feb 26, 2019
-
Investors
Medtronic
& 12 more
-
Employee Count
58
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Vertex Pharmaceuticals
(Sep 03, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Semma Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Semma Therapeutics
Semma Therapeutics has successfully raised a total of $158M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $114 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Semma Therapeutics
Semma Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Novartis and Vertex Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked |
Investor details for Semma Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Semma Therapeutics
Semma Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CytoSolv.
Investment portfolio details for Semma Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Biotech company developing encapsulating cell technology for indications in cell therapy; acquired by Semma Therapeutics in 2015
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Semma Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Semma Therapeutics
Detailed financials for Semma Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Semma Therapeutics Comparisons
Peer comparison for Semma Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Semma Therapeutics
Semma Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Sana Biotechnology, Cellino, Adocia and Pendulum, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Pendulum is focused on developing advanced probiotic solutions.
|
Detailed competitors of Semma Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Semma Therapeutics
Complete news archive for Semma Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Semma Therapeutics
Semma Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Semma Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Semma Therapeutics is a funded company, having raised a total of $158M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Semma Therapeutics is 58.
Semma Therapeutics engages in developing a cell therapy for Type 1 diabetes. It focuses on developing a cell therapy for patients who depend on insulin injections. It discovers a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells is sufficient to control blood glucose levels and the company is currently planning to file an IND for this program. This breakthrough technology has been exclusively licensed (from Meltons lab) to Semma Therapeutics for the development of cell-based therapy for diabetes.
Semma Therapeutics's top competitors include Sana Biotechnology, Adocia and Pendulum.
Semma Therapeutics has made 1 acquisition, including CytoSolv.
Semma Therapeutics has 13 investors. Key investors include Medtronic, Novartis, Vertex Pharmaceuticals, TD Securities, and Arch Venture Partners.